NDAORALSOLUTIONPriority Review
Approved
Sep 2020
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
XELJANZ (tofacitinib) by Pfizer. Approved for ulcerative colitis, rheumatoid arthritis, psoriatic arthritis and 1 more indications. First approved in 2020.
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XELJANZ (tofacitinib) is an oral small-molecule Janus kinase (JAK) inhibitor approved by the FDA on September 25, 2020. It is indicated for the treatment of autoimmune and inflammatory conditions, delivered as an oral solution formulation. The drug represents a targeted immunomodulatory approach to managing inflammatory disorders and fits within the competitive class of JAK inhibitors.
$0.3BPart D
1mo to LOEMechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (4)
Worked on XELJANZ at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.